News

Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F vaccine candidate demonstrated 85.7% efficacy in older patients with severe disease according to the phase 3 study.

Pegcetacoplan treatment effect accelerated between months 18-24 at reducing GA lesion growth in phase 3 DERBY and OAKS.

Hybrid visits were primarily for glaucoma (45.1%) and retinal issues (53.1%).

The treatment is the first pediatric indication of the treatment and the first treatment for younger patients with cGVHD.

Wearing glasses was inversely associated with COVID-19 in an unadjusted analysis, but the association did not remain when adjusting for confounders.

New research supports the inclusion of sleep disturbance in clinical evaluation and management in the treatment of Phelan-McDermid Syndrome (PMS) due to the drastic impact it can have on the quality of life for patients and their families.

Whole genome sequencing suggests both common and rare variants contribute to early onset drusen maculopathy.

Multivariate dimensional association scores resulted in an overall increase and normalization with age in the ADHD.

While investigators acknowledged the need for more high-quality, large-scale trials, cognitive behavioral therapy (CBT) serves as a promising intervention for insomnia in patients with cancer.

Regardless of frailty status, edoxaban 15 mg was associated with significantly reduced incidence of the study outcomes compared with placebo.

IBS-type symptoms were not linked to an increased likelihood of the need for glucocorticosteroids or flare, escalation, hospitalization, or intestinal resection.

Pharmacovigilance studies sifting through FDA adverse event reports confirm ocular side effects from PCSK9 inhibitors are infrequent and minor.

In this episode of Diabetes Dialogue, which was filmed just days after the conclusion of ADCES 22, our hosts take the time to dive deeper into the conference, their favorite sessions, and how the ADCES meetings have evolved to the changing role of diabetes care and education specialists over the years.

The investigational treatment SYNB1353 received FDA Fast Track Designation for homocystinuria (HCU), a rare metabolic disorder.

Vaccine-associated myocarditis was largely restricted to men younger than 40 years, according to the new findings.

Anhedonia had the highest expected influence in the most comprehensive network analysis, showing connections with negative and positive symptoms and functional domains.

Real time CGM was significantly greater time in range, lower time below range, and lower glycemic variability compared to intermittently scanned CGM.

The investigational therapy is being evaluated in a phase 2 study for the reduction in risk of major thrombotic cardiovascular events in patients with ESRD on hemodialysis.

The meta-analysis showed an increased odds ratio of developing postpartum depression when the maternal family had a history of psychiatric disorders.

Patients over 21 years who developed acne presented with different clinical characteristics than younger patients.

Announced on Aug. 22, the US FDA's clearance of the Omnipod 5 AID system in type 1 diabetes for patients aged 2 years and older comes less than 7 months after receiving clearance in patients aged 6 years and older.

Data suggest eyes with a higher ratio of drops taken versus prescribed were significantly more likely to achieve target IOP at 6 months or 1 year.

Endoscopic subscores can determine whether a patient is a suitable candidate for dose reduction.

Dextromethorphan HBr-bupropion HCI (Auvelity) is developed by Axsome Therapeutics.

No advantage was associated with blue light-filtering IOLs in terms of risk of all-cause or traffic-related injury and comfort with driving.

Data suggest most patients who receive a new diagnosis of PACG in the United States do not have a prior diagnosis of anatomical narrow angle.

In this article, readers will find a collection of the on-site coverage of the Association of Diabetes Care and Education Specialist (ADCES) 2022 annual meeting from Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives.

Occult HBV infection prevalence in blood donors was 0.06% in low-endemicity countries, 0.12% in intermediate-endemicity countries, and 0.98% in high-endemicity countries.